PURE Bioscience Reports $1.87 Million Net Loss with Revenue Growth to $1.66 Million

PURE Bioscience, Inc. reported its financial results for the nine months ending April 30, 2026, revealing a net loss of $1.87 million on total revenue of $1.66 million. This represents a slight improvement compared to the net loss of $2.07 million on revenue of $1.44 million for the same period in the previous fiscal year. The company's net product sales increased by 15% year-over-year, from $1.44 million to $1.66 million, driven primarily by higher sales of its flagship product, PURE® Hard Surface, which accounted for $1.55 million of total sales.

In terms of operational metrics, PURE Bioscience's gross profit for the nine-month period was $957,000, maintaining a gross margin of 58%, consistent with the previous year. However, the company experienced a rise in operating expenses, which totaled $2.54 million, down from $2.77 million in the prior year, largely due to reduced selling, general, and administrative costs. The company’s cash and cash equivalents increased significantly to $983,000 from $334,000 as of July 31, 2025, attributed to financing activities that generated $1.97 million.

Strategically, PURE Bioscience completed a private placement financing in April 2026, raising $1 million by issuing 18.13 million shares at a price of $0.0553 per share. This financing was primarily aimed at supporting ongoing research and development efforts and general corporate purposes. The company also reported an increase in its employee headcount, reflecting its commitment to expanding its operational capabilities and product development initiatives.

The company’s balance sheet showed total assets of $1.56 million, with total liabilities rising to $7.40 million, resulting in a stockholders' deficiency of $5.84 million. This deficiency raises concerns about the company's ability to continue as a going concern, as highlighted in the filing. The management noted that future capital requirements will depend on various factors, including product acceptance, regulatory approvals, and the success of its partners in selling its products.

Looking ahead, PURE Bioscience aims to leverage its proprietary technology platform to develop additional antimicrobial products and expand its market presence. The company is focused on enhancing its distribution network and exploring new product applications, which it believes will drive future growth. However, the management cautioned that the company must continue to secure financing to support its operations until it can achieve positive cash flow from its activities.